Header a MOSA O2

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

HOME

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias
Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

CONTACT

Header_Line_MOSA - www.mosao2.org - Medical Oxygen Society of the Amercias

3D Map of the Americas - MOSA - Medical Oxygen Society of the Americas

Header Logo - MOSA - Medical Oxygen Society of the Americas
Google Language Translator - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org
   
   
HOME PAGE menu white arrow - MOSA - www.mosao2.org - Medical Oxygen Society of the Americas
NEWS / RESEARCH menu white arrow - MOSA - www.mosao2.org - Medical Oxygen Society of the Americas
   

bg grey mosao2

MOSA Membership - Click Here to Enroll - www.mosao2.org - Medical Oxygen Society of the Americas
bg grey mosao2

MOSA Newsletter - Sign Up Here - www.mosao2.org - Medical Oxygen Society of the Americas

bg grey mosao2
MOSA Study Groups - Sign Up Here - www.mosao2.org - Medical Oxygen Society of the Americas
bg grey mosao2
 
Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org


MOSA - Article

Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org


Circulating 25-Hydroxy Vitamin D Levels Predict Survival in Early-Stage Non-Small-Cell Lung Cancer Patients

Logo - MOSA - Medical Oxygen Society of the Americas
Spacer - MOSA - Medical Oxygen Society of the Americas - www.mosao2.org

 

http://www.ncbi.nlm.nih.gov/pubmed/17290055

http://www.polymvasurvivors.com/index.html

 

Early stage lung cancer patients who were diagnosed in the summer and had the highest levels of vitamin D had a five-year survival of 73% compared to 30% for those diagnosed in the winter with low vitamin D levels.

 

 

________________________________________

 

 

Circulating 25-Hydroxy Vitamin D Levels Predict Survival in Early-Stage
Non-Small-Cell Lung Cancer Patients

 

 

Abstract

 

PURPOSE:

Our previous analyses suggested that surgery in the summertime with higher vitamin D intake is associated with improved survival in patients with early-stage non-small-cell lung cancer (NSCLC). We further investigated the results of circulating 25-hydroxyvitamin D (25[OH]D) levels on overall survival (OS) and recurrence-free survival (RFS) in NSCLC patients.

 

 

________________________________________

 

 

PATIENTS AND METHODS:

Among 447 patients with early-stage NSCLC, data were analyzed using Cox proportional hazards models, adjusting for age, sex, stage, smoking, and treatment.

 

 

________________________________________

 

 

RESULTS:

The median follow-up time was 72 months (range, 0.2 to 141), with 161 recurrences and 234 deaths. For OS, the adjusted hazard ratio (AHR) was 0.74 (95% CI, 0.50 to 1.10; Ptrend = .07) for the highest versus lowest quartile of 25(OH)D levels. Stratified by stage, a strong association was observed among stage IB-IIB patients (AHR, 0.45; 95% CI, 0.24 to 0.82; Ptrend = .002), but not among stage IA patients (AHR, 1.10; 95% CI, 0.62 to 1.96; Ptrend = .53).

 

Similar effects of 25(OH)D levels were observed among the 309 patients with dietary information (AHR, 0.74; 95% CI, 0.46 to 1.17; Ptrend = .19). For the joint effects of 25(OH)D level and vitamin D intake, the combined high 25(OH)D levels and high vitamin D intake (by median) were associated with better survival than the combined low 25(OH)D levels and low vitamin D intake (AHR, 0.64; 95% CI, 0.42 to 0.98; Ptrend = .06).

 

Again, stronger associations were observed among stage IB-IIB than IA patients. Similar effects of 25(OH)D levels and vitamin D intake were observed for RFS.

 

 

________________________________________

 

 

CONCLUSION:

Vitamin D may be associated with improved survival of patients with early-stage NSCLC, particularly among stage IB-IIB patients.

 

 

________________________________________

 

 

http://www.ncbi.nlm.nih.gov/pubmed/17290055

http://www.polymvasurvivors.com/index.html

 

   

 

 

Copyright @ 2011 www.mosa02.com. All Rights Reserved.


Disclaimer:

While every effort has been made to ensure that the information and data provided on this website are correct, no guarantee can be provided that
the information it contains is completely error-free. MOSA shall not be held liable for information and data that is not up-to-date, correct or complete.

MOSA reserves the right to edit, change or add to the information and data provided without prior notice. This website is produced and published
so that you can broaden your health education and options. Please consult your physician before considering any therapy.